Org.nr 979 455 518 2023 → 2024 Year-over-year analysis

ACD PHARMACEUTICALS AS: årsregnskap 2024 vs 2023

Shrank 16% on revenue, slipped into loss, cash halved-plus

approved 2025-05-31; registry 2025-07-29; journal 2025 712821

Summary

What changed

Comparing Årsregnskap 2024 with 2023 for ACD PHARMACEUTICALS AS. Revenue 29.42m NOK → 24.67m NOK (-16.2%). Net result +3.65m NOK → -967.1k NOK.

Pressures included: revenue fell; operating result weakened; fell into a net loss.

Also worth watching: paid-in equity reduced. All figures are taken from the published annual accounts for ACD PHARMACEUTICALS AS.

At a glance

Revenue

29.42m NOK 24.67m NOK

-16.2%

Operating result

+4.85m NOK -3.82m NOK

-178.9%

Net result

+3.65m NOK -967.1k NOK

-126.5%

Cash

415.2k NOK 19.3k NOK

-95.3%

Total assets

32.90m NOK 75.44m NOK

+129.3%

↓
Revenue fell

Operating income / revenue moved from 29.42m NOK to 24.67m NOK (-16.2% YoY). Calculated
↓
Operating result weakened

Operating result +4.85m NOK → -3.82m NOK (op. margin 16.5% → -15.5%). Calculated
↓
Fell into a net loss

Net result flipped from 3.65m NOK profit to a loss of 967.1k NOK. Calculated
↓
Cash fell

Bank deposits 415.2k NOK → 19.3k NOK (-95.3% YoY). Calculated
↓
COGS moved

COGS / varekostnad 3.03m NOK → 8.30m NOK (+174.0% YoY). Calculated

·
Paid-in equity reduced

Paid-in equity fell 13.61m NOK → 13.39m NOK — check capital reduction, conversion, or reclassification. Interpretation